home / stock / bovnf / bovnf short
Short Information | Bioinvent Ab (OTCMKTS:BOVNF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 92,794 |
Total Actual Volume | 92,794 |
Short Trends | |
---|---|
Cover Days | 0 |
Short Days | 8 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 4,640 |
Average Short Percentage | 40.00% |
Is there a BOVNF Short Squeeze or Breakout about to happen?
See the BOVNF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
02-08-2023 | $0 | $4.7 | $0 | $0 | 14 | 14 | 100% |
01-24-2023 | $0 | $4.7 | $0 | $0 | 80 | 80 | 100% |
12-21-2021 | $5.49 | $5.49 | $5.49 | $5.49 | 100 | 100 | 100% |
12-16-2021 | $5.25 | $5.25 | $5.25 | $5.25 | 1,000 | 1,000 | 100% |
12-10-2021 | $5.25 | $5.25 | $5.25 | $5.25 | 1,000 | 1,000 | 100% |
06-29-2021 | $6.84 | $6.84 | $6.84 | $6.84 | 600 | 600 | 100% |
12-23-2019 | $0.14 | $0.14 | $0.14 | $0.14 | 40,000 | 40,000 | 100% |
03-22-2019 | $0.1724 | $0.1724 | $0.1724 | $0.1724 | 50,000 | 50,000 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Bioinvent Ab Company Name:
BOVNF Stock Symbol:
OTCMKTS Market:
The two poster presentations will report - first combination data from the Phase 1/2a study with BI-1808 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), as well as an update on monotherapy arm combination data from the Phase 1/2a study with BI-1206 in combin...
LUND, SWEDEN / ACCESSWIRE / April 24, 2024 / BioInvent International (STO:BINV) "During the first quarter of the year, we continued making excellent progress with our clinical pipeline targeting TNFR2 and FcyRIIB, building on the momentum we generated during a very successful 2023. Looking ahe...
LUND, SWEDEN / ACCESSWIRE / April 4, 2024 / BioInvent International AB (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immunomodulatory antibodies for cancer immunotherapy, today announced that the Annual Report for 2023 has been pu...